March 28, 2017
Kyowa Hakko Kirin said on March 27 that the c-MET inhibitor tivantinib could not deliver a statistically significant improvement versus placebo in the primary endpoint of progression-free survival (PFS) in a Japan PIII study for the treatment of hepatocellular carcinoma...read more